We prospectively studied and compared the usefulness of Kampo medicine (Sino-Japanese traditional herbal medicine)``Toki shakuyaku san'' and an oral iron preparation in the treatment of hypochromic anemia associated with uterine myoma. The study subjects consisted of 25 patients who were diagnosed as having hypochromic mild to moderate anemia associated with menorrhagia attributable to uterine myoma. They were divided into the Toki shakuyaku san group (n＝10) and the oral iron group (n＝15). We monitored the blood counts, subjective symptoms, and occurrence of side eŠects after oral administration of either preparation for 4 and 8 weeks in these subjects. In regard to the blood counts and improvement of the laboratory parameters of anemia, while marked improvement was observed in the oral iron group, no signiˆcant improvement was noted in the Toki shakuyaku san group. On the other hand, in terms of improvement of the signs and symptoms of anemia, such as facial pallor, spoon-shaped nails and dizziness, the latter group also showed signiˆcant improvement. In addition in the Toki shakuyaku san group, resolution of symptoms such as hypermenorrhea, dysmenorrhea, feeling cold, dizziness, headache and shoulder stiŠness was also noted. While side eŠects were encountered in 80.0％ of patients in the oral iron group, no signiˆcant side eŠects were observed in the Toki shakuyaku san group. From theseˆndings, it is considered that Toki shakuyaku san may be useful for resolving the symptoms of mild or moderate anemia associated with uterine myoma.
INTRODUCTION
Iron supplements are widely prescribed for the treatment of iron deˆciency anemia. 1, 2) Indiscriminate use of oral iron, however, may cause hemochromatosis or cell injury, 3) furthermore, the high frequency of gastrointestinal side eŠects reduces the medication compliance rate of the patients. Since combined prescription of iron tablets and a drug to counteract the gastrointestinal side eŠects would increase the medical care expenditure, 4) appropriate use of oral iron preparation is nowadays required. In a previous study, we retrospectively examined the eŠects, safety and cost-eŠectiveness of Toki shakuyaku san, Kampo medicine (Sino-Japanese traditional herbal medicine), in the treatment of iron deˆciency anemia, in comparison with those of an oral iron supplement and reported its favorable eŠects. 4) Toki shakuyaku san is composed of substances derived from 6 medicinal plants, including toki, senkyu, shakuyaku, sojutsu, takusha, and bukuryo. This Kampo medicine is known to be eŠec-tive in the treatment of physically weak women with indeˆnite symptoms, perhaps because of its eŠects of inducing smooth muscle relaxation and facilitating hemopoiesis and adequate water level control in body. 5) Toki shakuyaku san is one of the most widely prescribed Kampo medicines for the treatment of gynecological disorders, such as infertility, dysmenorrhea and climacteric disturbances, in addition to being used for anemia. 6) Since the Kampo medicine has been conˆrmed to have no teratogenicity in animal experiments, 7) it has also been used in the treatment of hydremia of pregnancy. 5) Much, however, still remains unknown about the mechanism of actions of this Kampo medicine.
Uterine myoma is known to occur in 5 to 10 ％ of women in the reproductive age group, and 10 to 20 ％ of women over the age of 40 years. 8) The frequency of menorrhagia or dysmenorrhea is high (87.5％) in patients with uterine myoma, 9) and the resultant anemia and the symptoms associated with it substantially depress the quality of life (QOL) of these patients. Thus, treatment of patients with uterine myoma is important. But the e‹cacy and safety of Toki shakuyaku san has not been evaluated for anemia patients with uterine myoma, yet. In this prospective study, we compared the e‹cacy and safety of Toki shakuyaku san and an oral iron supplement in the treatment of anemia associated with menorrhagia in cases of uterine myoma, by assessing the improvements of the signs and symptoms and laboratory abnormalities induced by either drug in these patients.
SUBJECTS AND METHODS

Subjects
The study were subjects who visited the Department of Obstetrics and Gynecology, Kitasato University Hospital as outpatients between August 1, 1999 and January 31, 2000, and it's subjects were diagnosed as having mild to moderate anemia (Hb 8.0 to 12.0 g/dl) associated with uterine myoma. The iron deˆciency anemia was diagnosed at the value of RBC, Hb, Ht, MCV, MCH and MCHC. In total, 25 patients were enrolled in the study. All the patients gave informed consent for the use of their laboratory and clinical data for this prospective study. The patients were randomly assigned to one of two groups in the index mainly Hb value; the Toki shakuyaku san group (n＝10), in which the patients received 2.5 g of Toki shakuyaku san extract granule (Tsumura Co., Ltd., Tokyo, Japan) thrice daily before meals, and the oral iron group (n＝15), in which patients received one to two tablets of sodium ferrous citrate (Ferromiatablets, Eisai Co., Ltd., Tokyo, Japan) daily after meals in 1 to 2 divided doses. Of the 25 patients enrolled in this study, severe side eŠects were encountered in 2 patients in the oral iron group. These two patients were excluded from the study at the discretion of the physician. The mean (± SE) age was 45.40±1.99 in the Toki shakuyaku san group (n＝10), and 42.85±1.68 in the oral iron group (n＝13).
Parameters Examined
The clinical severity of the uterine myoma was assessed by the attending physician. On the same day, hematological testing was performed to determine the total white blood cell count (WBC), diŠerential white cell count, including eosinophils (EOS), lymphocytes (LYM), monocytes (MONO), basophils (BASO) and neutrophils (NEUTRO), the red blood cell count (RBC), hemoglobin (Hb), hematocrit (Ht), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), reticulocyte count, platelet count (PLT), prothrombin time (PT), and activated partial thromboplastin time (APTT). Blood biochemical tests were also carried out, to determine the serum levels of total protein (TP), albumin (Alb), total bilirubin (TB), direct bilirubin (DB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), g-glutamyl
total iron-binding capacity (TIBC), and ferritin. These laboratory parameters were recorded on the clinical record form by a pharmacist involved in the study. The pharmacist also interviewed each patient to assess the signs and symptoms associated with iron deˆciency anemia in these patients with uterine myoma and recorded theˆndings on the clinical record form ( Table 1) . Since Toki shakuyaku san is known to alleviate menopausal disturbances as well, symptoms of climacteric disturbances were additionally included in the interview items. The interview and it's items were decided after much discussion among the participating physicians and pharmacists. The observation period of the patients was 2 months. The clinical, hematological and blood biochemical parameter assessment was performed at baseline, and at 4 and 8 weeks after the start of the study treatment. The results were reported to the physician, and appropriate medical interventions were undertaken, if necessary. The changes in the study parameters over time were analyzed. The pharmacist also made enquiries about any side eŠects of the study drugs noted by the patient at 4 and 8 weeks after the start of the treatment, along with regular instruction on dosage and administration for ambulatory patients. Any abnor- Severityscale; 0(none: score 0), 1(slight: very slight and infrequent symptoms: score 1), 2(mild: mild symptoms causing a little distress: score 2), 3(moderate: moderate symptoms causing some distress: score 3), 4(severe: severe symptoms that are di‹cult to tolerate, causing much distress and interference with daily activities: score 4). malˆndings were reported to the physician, who administered appropriate treatment where required.
Assessment of Signs and Symptoms
For assessment of the signs and symptoms of anemia, 12 symptom parameters were included: pallor, spoon shape of the nails (koilonychias), soreness of the mouth and cracks at the angles, palpitations, dizziness on standing, di‹culty in waking up, easy fatigability, malaise, shortness of breath, swallowing di‹culty, deviant food habits, thrusting sensation of food on the tongue, and occult blood in the feces. The 7 symptom parameters of uterine myoma assessed were dysmenorrhea, menorrhagia, low back pain, lower abdominal pain, constipation, dysuria, and increased urinary frequency. The climacteric disturbance index was assessed from 22 symptoms, including hot ‰ush-es, bursts of sweating, cold feeling in the lower part of the body, cold hands and feet, dizziness, nausea, headache, tinnitus, shoulder stiŠness, tingling pain in the hands and feet, leg cramps, diarrhea, bloated feeling, edema, insomnia, shallow sleep, irritability, formication, anxiety, numbness of the hands and feet, loss of feeling in the hands and feet, and nervousness. These signs and symptoms were scored on a scale of 0 to 4 as follows, at baseline and after 4 and 8 weeks of the study treatment: 0 (none), 1 (slight: very slight and infrequent symptoms), 2 (mild: mild symptoms causing a little distress), 3 (moderate: moderate symptoms causing some distress), and 4 (severe: severe symptoms that are di‹cult to tolerate, causing much distress and interference with daily activities) ( Table  1) .
Statistical Analysis Wilcoxon's rank-sum test was used to compare the improvement in the Toki shakuyaku san group and the oral iron group. Changes in the laboratory parameters and sings/symptoms over time were analyzed by Wilcoxon's signedranks test. P＜0.05 was considered to denote statistical signiˆcance.
RESULTS
Laboratory Data
The hematological and blood biochemical parameters indicative of the degree of anemia at baseline are shown in Table 2 . No signiˆcant diŠerences were noted between the two groups in terms of the RBC, Hb, Ht, reticulocyte count, MCV, MCH, MCHC, TIBC, or serum ferritin level at baseline. Since the serum Fe level at baseline was signiˆcantly higher in the Toki shakuyaku san group than in the oral iron group, changes in the serum Fe level relative to the baseline were compared between the two groups after 4 and 8 weeks of treatment. Concerning the blood biochemical parameters, no signiˆcant diŠerences or abnormal values were found between the two groups in terms of the TP, Alb, TB, DB, AST, ALT, ALP, g-GTP, CHE, LDH, CK, AMY, TC, TG, BUN, Cr, UA, Na, K, Cl, Ca, P, TIBC, or ferritin at baseline. Furthermore, no signiˆcant diŠerences in the hematological and blood biochemical data at baseline were observed between patients who had subjective symptoms of anemia and patients who did not ( Table 3) .
Changes in Laboratory Findings over Time
The laboratory parameters indicative of the severity of anemia are shown in Table 2 , together with other laboratory parameters that showed changes relative to the baseline levels after 4 and 8 weeks of the study treatment. In the Toki shakuyaku san group, while no changes in the Hb, Ht, MCV, MCH, and TIBC were observed, no deterioration of the anemic condition was observed either in any of the patients. Concerning the serum Fe level, the level at the baseline was signiˆcantly higher in the Toki shakuyaku san group than in the oral iron group, therefore changes relative to the levels at baseline were used for the analysis. While no signiˆcant changes from the baseline levels were observed in the serum Fe level in the Toki shakuyaku san group (1 ±8mg/dl after 4 weeks of the treatment and -10±6 mg/dl after 8 weeks of treatment), the serum Fe levels showed signiˆcant increase in the oral iron group. This diŠerence could, at least in part, be related to the serum Fe level at baseline being closer to the normal range in the Toki shakuyaku san group than in the oral iron group. In the Toki shakuyaku san group, intersubject and intrasubject variability of the serum ferritin level was noted, the MCHC increased signiˆcantly relative to the baseline value after 8 weeks of treatment, and the RBC and reticulocyte count also showed a tendency to increase. It was noteworthy that the PLT also increased signiˆcantly in this group, while the APTT decreased signiˆcantly and the PT showed a decreased tendency.
On the other hand, in the oral iron group, the RBC, Hb, Ht, MCV, MCH, MCHC, and serum ferritin level showed signiˆcant increase relative to the baseline values, however TIBC showed signiˆcant decrease and no signiˆcant change in the reticulocyte count 
Toki-shakuyaku-sangroup (n＝10), Oral iron preparation group (n＝13). Each values represents mean±S.E. Signiˆcantly diŠerent before and after the drug administration at p＜0.05 by Wilcoxon's rank-sum test. # Signiˆcantly diŠerent between Toki-shakuyaku-san and oral iron preparation at p＜0.05 by Wilcoxon's signed-ranks test.
was observed. The serum Fe level increased signiˆcantly after 4 weeks (98±24 mg/dl) and 8 weeks (68±31 mg/dl) of the study treatment relative to the levels at baseline in analyzing it as changes. The PLT decreased signiˆcantly relative to the baseline count in this group, in contrast to the signiˆcant increase relative to the baseline count observed in the Toki shakuyaku san group, mentioned above.
Improvement of Signs and Symptoms
The signs and symptoms were assessed at baseline, and after 4 and 8 weeks of the study treatment. Parameters which showed changes during the study period are shown in Table 3 ; higher scores indicate worse symptoms.
Concerning the symptoms of anemia, pallor, spoon shape of the nails, and dizziness on standing resolved signiˆcantly as compared to the baseline in the Toki shakuyaku san group. Soreness of the mouth and cracks at the angles, and shortness of breath also tended to improve in this group. In the oral iron group, improvement of the anemic condition was re‰ected by improvement in the laboratory parameters, as also by resolution of the pallor and spoon shape of the nails relative to the baseline. Dizziness on standing and shortness of breath also improved signiˆcantly after 8 weeks of treatment in this group. In regard to the symptoms of uterine myoma and symptoms associated with climacteric disturbances, such as menorrhagia, dysmenorrhea, cold feeling in the lower part of the body, cold hands and feet, dizziness, headache, and shoulder stiŠness, signiˆcant improvement was noted after 8 weeks of treatment in the Toki shakuyaku san group; the bursts of sweating and tingling pain in the hands and feet also tended to improve in this group. In contrast, no such remarkable improvement in subjective symptoms was observed in the oral iron group.
Side EŠects
During the interview by the pharmacist, the patients were asked about the occurrence of side eŠects during the study period. No side eŠects were encountered in the Toki shakuyaku san group, while 80.0％ of patients in the oral iron group reported one or more side eŠects, including heartburn (46.7 ％), nausea (46.7％), vomiting (20.0％), diarrhea (20.0％), constipation (13.3％), abdominal distention (13.3％), anorexia (6.7％), and soft feces (6.7 ％) (Fig.1) . Patients with abnormalˆndings were referred to a physician, and appropriate medical treatment was prescribed where necessary, including additional prescription of gastrointestinal drugs. In two patients, the oral iron supplement had to be stopped because of severe vomiting.
DISCUSSION
In this prospective study, we compared the e‹cacy and side eŠects of Toki shakuyaku san and an oral iron supplement in the treatment of anemia associated with menorrhagia attributable to uterine myoma, by assessing the improvement of signs and symptoms and laboratory biochemical parameters in these patient following either drug administration. Iron is needed for the production of hemoglobin. In the present study, oral iron supplementation improved the hematological and blood biochemical parameters, and also led to resolution of some signs and symptoms of anemia. However, gastrointestinal side eŠects were encountered in more than 80.0％ of patients receiving the oral iron supplement, resulting in a poor medication compliance rate. In the Toki shakuyaku san group, while there was no signiˆcant improvement in the laboratory parameters re‰ective of the severity of anemia, marked resolution was noted of the symptoms and signs of anemia, such as pallor, koilonychia, and dizziness on standing, as also of those related to the uterine myoma, including menorrhagia and dysmenorrhea, and the climacteric symptoms of shoulder stiŠness, dizziness, poor circulation, headache, etc without side eŠect. Toki shakuyaku san has been reported to be eŠective in the treatment of anemia of pregnancy. 5) Anemia of pregnancy is related to increase in the blood volume in normal pregnant women, when the increase in erythrocyte mass lags behind the increase in plasma volume, leading to blood dilution. This condition is sometimes called physiological anemia. Toki shakuyaku san has been known to improve anemia in pregnant women by facilitating water level control in body and hematopoiesis. The purpose of this study was to treat iron-deˆciency anemia associated with menorrhagia attributable to uterine myoma. The water level control in body and hematopoietic eŠects of Toki shakuyaku san may not be useful for improving laboratory parameters in patients with anemia due to excessive menstrual bleeding. Another study has described that Toki shakuyaku san improved ovarian function, which led to the alleviation of excessive menstrual bleeding not related to uterine myoma. 10) Several investigators have referred to the eŠect of Toki shakuyaku san on menorrhagia, coagulation abnormalities and dysmenorrhea associated with uterine myoma. Theseˆndings suggest that Toki shakuyaku san may exert analgesic, spasmolytic, and hemostatic eŠects by controlling the adhesiveness of erythrocytes and preventing oxygen deˆciency in tissues. 9) Furthermore, in this study, the hemostatic eŠect of Toki shakuyaku san may also contribute to the alleviation of the symptoms of anemia, considering the observed relief of menorrhagia, increased platelet count, and reduction in APTT in the patients. No other study, however, has reported an increase in platelet count following the administration of Toki shakuyaku san. Further studies are required to clearly elucidate the mechanism of actions in Toki shakuyaku san. It might be considered that the relief of the subjective symptoms of climacteric disturbances is related to blood circulation, which suggests that the improvement of blood circulation in Toki shakuyaku san as reported in experiments. 11) Overall, in order to supply the iron of the anemia, it is considered that the iron preparation is useful. Toki shakuyaku san may be considered to be beneˆ-cial as an alternative medicine in the treatment of mild or moderate anemia associated with uterine myoma, when oral iron supplements as theˆrst drugs of choice induce severe side eŠects. The use of this Kampo medicine could be expected to improve the patient's QOL by resolving the symptoms of anemia, menorrhagia, dysmenorrhea and climacteric disturbances in these cases.
Finally, combined therapy using Toki shakuyaku san with an oral supplement for anemia associated with uterine myoma may oŠer promise, since the same combination has been shown to be eŠective in the treatment of anemia of pregnancy. 12) 
